ZymoGenetics Inc.

Bristol-Myers Squibb and ZymoGenetics Present Final Phase 1b Results for PEG-Interferon Lambda in Hepatitis C.
Hepatitis Weekly; 11/16/2009; 1405 words; ...Squibb Company (NYSE: BMY) and ZymoGenetics, Inc. (NASDAQ: ZGEN) today presented...Bristol-Myers Squibb Company Inc., Clinical Trial Research...Inhibition, Viral Therapy, Virology, ZymoGenetics Inc.. This article was prepared...

ZymoGenetics Reports Third Quarter 2009 Financial Results.(Financial report)
Clinical Trials Week; 11/16/2009; 1524 words; ZymoGenetics, Inc. (NASDAQ:ZGEN) reported improved...cost reduction efforts (see also ZymoGenetics, Inc.). "The company is making important...D., Chief Executive Officer of ZymoGenetics. "RECOTHROM sales trends continue...

Patent No. 7,615,611 Issued on Nov. 10, Assigned to ZymoGenetics for Human Cytokine Receptor (Washington Inventors)
US Fed News Service, Including US State News; 11/11/2009; 382 words; ...receptor. The inventors were issued U.S. Patent No. 7,615,611 on Nov. 10. The patent has been assigned to ZymoGenetics Inc., Seattle. According to the abstract released by the U.S. Patent & Trademark Office: "Cytokines and...

ZymoGenetics to Webcast Presentation at Oppenheimer Healthcare Conference.(Conference news)
Biotech Week; 11/11/2009; 1045 words; ZymoGenetics, Inc. (NASDAQ: ZGEN) announced that...50 a.m. Eastern Time (see also ZymoGenetics, Inc.). A live webcast of the presentation...Protein Therapies, Proteomics, ZymoGenetics Inc., ZymoGenetics Inc. This article...

ZymoGenetics Releases 3Q 2009 Financial Results.
Health & Beauty Close-Up; 11/10/2009; 1031 words; ZymoGenetics, Inc. has reported improved financial...D., Chief Executive Officer of ZymoGenetics. "Recothrom sales trends continue...Interferon lambda Phase 2 clinical trial. ZymoGenetics is focused on the creation of novel...